This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.
Program Description
A number of genetic mutations, including EGFR, ALK, ROS1, and KRAS, among others, have necessitated the rapid expansion of targeted therapies for the treatment of non-small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed to inhibit ROS1 dysregulated signaling and KRAS mutations, with others are being investigated in promising clinical trials. This activity will detail safety and efficacy data for recently approved and investigational therapies targeting ROS1-rearranged and KRAS-mutated NSCLC as well as the utilization of combination targeted therapy regimens to overcome observed TKI resistance mechanisms. Because of the complexity of oral TKI therapies, oncology pharmacists must be prepared to address adverse effects, adherence, and access issues to optimize patient care and self-management. Panelists will also discuss patient cases and share insight into monitoring and management strategies based on patient- and disease-specific factors.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 26, 2023
Expiration date: April 26, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the role of biomarker testing and characteristics of KRAS-mutant and ROS1-rearrangements in non-small cell lung cancer (NSCLC)
- Analyze the evidence for the efficacy and safety of the expanding treatment options in KRAS-mutant and ROS1-rearranged NSCLC
- Identify strategies to prevent and mitigate adverse effects and promote adherence in patients receiving oral tyrosine kinase inhibitor therapies for NSCLC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
